Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genetic testing for neonates must be restricted, says EC:

This article was originally published in Clinica

Executive Summary

"Genetic testing can certainly help in the early detection of illnesses, but can never be made compulsory". That is the statement being made by European Research Commissioner Philippe Busquin, who denies stories in the media, which has reported that he has called for genetic testing of all newborn babies in Europe. This issue has come to the fore following a recent presentation of recommendations by a Commission expert group looking at the ethical legal and social implications of genetic testing. This group has proposed that for "rare but serious diseases for which treatment is available, member states should introduce universal neonatal screening". A statement issued by the Commission has confirmed that the group "is not asking the European Commission nor member states to launch any global post-natal genetic screening programme, but to consider screening only for those rare and serious diseases for which treatments already exist". For more details on the findings of the group, see: genetic/index-en.htm

You may also be interested in...

Health And Wellness Trademark Review 31 March, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Faster, Better? Fujitsu, Polarisqb 'Quantum-Inspired' Tech Speeds Discovery

Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.

Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts